In 2023, sales of non-steroid anti-inflammatory and antirheumatic medicines in Canada were recorded at approximately 215 million US dollars. Forecasts for the subsequent years indicate a gradual decline: 204.6 million in 2024, 200.8 million in 2025, 197.8 million in 2026, 195.3 million in 2027, and 193.3 million in 2028. This showcases a downward trend.

The year-on-year percentage decline between 2024 and 2025 is projected at approximately -1.9%. The compound annual growth rate (CAGR) from 2024 to 2028 is estimated to be -1.4% per year, highlighting a continuous reduction in sales value.

Future trends to watch for include:

Innovation in drug formulations and delivery methods to mitigate side effects.
Potential impact of healthcare policy changes and drug price negotiations.
Increased focus on alternative therapies, including biologics and personalized medicine.
Growing awareness and preventive measures for diseases causing inflammation.